Study Title
CA224-069: A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants with Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Protocol ID
CA224-069
Disease (Sub Disease)
Non-Hodgkin Lymphoma
Diagnosis Stage
Relapsed/Refractory
Location
NSW, QLD, WA
Sponsor
Bristol-Myers Squibb
Links
Trial Status
Open
Sites
Perth Children's Hospital
Queensland Children's Hospital
Sydney Children's Hospital
Queensland Children's Hospital
Sydney Children's Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
up to 30 Years
International registry ID's
NCT05255601
| Study Title | CA224-069: A Phase 1/2 Study of the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants with Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma |
|---|---|
| Protocol ID | CA224-069 |
| Disease (Sub Disease) | Non-Hodgkin Lymphoma |
| Diagnosis Stage | Relapsed/Refractory |
| Location | NSW / QLD / WA |
| Sponsor | Bristol-Myers Squibb |
| Links | https://clinicaltrials.gov/ct2/show/NCT05255601 |
| Trial Status | Open |
| Trial Open Date | 01/11/2022 |
| Sites | Perth Children's Hospital / Queensland Children's Hospital/ Sydney Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | up to 30 Years |
| International registry ID's | NCT05255601 |